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Abstract  
Purpose: To evaluate a proposed method for objective measurement of vitreous 
inflammation using an spectral domain optical coherence tomography (SD-OCT) 
device in a large cohort of uveitis eyes, including pseudophakic eyes and 
vitrectomized eyes. 
Design: Retrospective, observational, cohort study.  
Methods: One-hundred five uveitis eyes (105 patients) with different vitreous haze 
score grades according to standardized protocols and corresponding SD-OCT 
images (Cirrus HD-OCT, Carl Zeiss Meditec) were included. Clinical data recorded 
included phakic status, previous vitreo-retinal surgery and anterior chamber (AC) 
cells and flare. SD-OCT images were analyzed using custom software which 
provided absolute measurements of vitreous (VIT) and retinal pigment epithelium 
(RPE) signal intensities, that were compared to generate a relative optical density 
ratio with arbitrary units (VIT/RPE-Relative intensity) and compared to VHS. 
Results: VIT/RPE-relative intensity showed a significant positive correlation with 
vitreous haze score (r = 0.535, p<0.001) that remained significant after adjusting 
for factors governing media clarity such as AC cells, AC flare and phakic status 
(R2-adjusted = 0.424, p<0.001). Significant differences were also observed 
between the different vitreous haze score groups (p<0.001). Preliminary 
observation did not observe differences in VIT/RPE-relative intensity values 
between phakic and pseudophakic eyes (0.3522 vs 0.3577, p=0.48) and non-
vitrectomized and vitrectomized eyes (0.3540 vs 0.3580, p=0.52) overall and 
respectively for each vitreous haze score subgroups. 
Conclusions: VIT/RPE-relative intensity values provide objective measurements 
of vitreous inflammation employing an SD-OCT device. Phakic status and previous 
vitrectomy surgery do not appear to influence these values, although these 
preliminary findings need validation in future studies.  
 
Abstract  (MUST be submitted as a separate file)
11th June 2015 
Dear Thomas J. Liesegang, MD, 
Editor-In-Chief, 
American Journal of Ophthalmology 
 
Thank you for considering the manuscript below, 
 
“Evaluation of objective vitritis grading method using optical coherence 
tomography: influence of phakic status and previous vitrectomy”  
 
for publication as a “Original article” in American Journal of Ophthalmology.  
 
This manuscript has been drafted according to the Instructions for Authors and it 
has not been submitted before to any other journals.  
 
The current method for assessment of vitreous inflammation in uveitis eyes is the 
National Eye Institute´s vitreous haze score (VHS) system, which is subjective, 
non-continuous and poorly discriminatory at the lower levels of vitreous 
inflammation, representing a challenge for clinical assessment particularly in 
clinical trial scenarios. For these reasons Keane et al (Ophthalmology, 
2014;121(9):1706-14) recently proposed a novel method to obtain objective 
measurements of vitreous inflammation using optical coherence tomography, 
determining vitreous/retinal pigment epithelium relative optical density ratios which 
showed good correlation with clinical grades of VHS. 
 
However, the original study had a number of limitations: 1) it was too small to allow 
subgroup analysis of factors that might render the technique unreliable, notably 
phakic status or previous vitreoretinal surgery, 2) it employed a unique OCT device 
from a single vendor, and 3) the results needed to be replicated in a) a different 
cohort of patients, b) by a different team of OCT technicians and c) independent 
analysers to ascertain the method validity and applicability to multiple end-users.   
 
The aims of this study is to validate the OCT-derived vitritis quantification method 
in a larger series of eyes, using an alternative spectral domain OCT platform in a 
geographically and demographically distinct study population, and to determine the 
influence of phakic status or previous vitreo-retinal surgery on these 
measurements. 
 
I confirm that every author has seen and agrees with the final draft of the 
manuscript. 
 
Yours sincerely, 
Javier Zarranz-Ventura MD PhD FEBO 
Corresponding author 
Phone: +34 660008417  
Email: jzarranz@hotmail.com; zarranz@clinic.ub.es.  
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Introduction 
The current method for assessment of the inflammatory status in eyes with uveitis 
is almost entirely based on subjective clinical estimates according to standardized 
scales for both anterior and posterior segment.1, 2 In the case of vitreous 
inflammation, the gold standard has been the National Eye Institute system for 
grading of vitreous haze, often known as the Nussenblatt scale.2 This classification 
is based on estimation of the clarity of the fundus when viewed with the indirect 
ophthalmoscope and a 20D lens in comparison to a set of reference photographs. 
The National Eye Institute vitreous haze score has been approved as a surrogate 
endpoint by the United States Food and Drug Administration and is used as a 
primary outcome measure in the majority of clinical trials in uveitis. Vitreous haze 
score does, however, have a number of limitations: it is subjective, with only 
moderate interobserver agreement3, 4; it is non-continuous, grading disease activity 
in large steps between vitreous haze score categories; it is poorly discriminatory at 
the lower levels of vitreous inflammation that represents the majority of patients 
with active vitreous inflammation (i.e. +0.5, +1 vitreous haze score) and therefore 
arguably a challenge for clinical assessment, particularly in clinical trial scenarios. 
 
There is consensus in the uveitis community for the need of objective measures of 
inflammatory activity in sight-threatening uveitis. With this aim, a recent proof-of-
concept study demonstrated that spectral domain optical coherence tomography 
(OCT) images could be processed to obtain objective measurements of vitreous 
inflammation in eyes with intermediate, posterior and panuveitis.5 This method was 
based on the determination of the signal intensity of the vitreous compartment, 
which was then compared to that of the retinal pigment epithelium (RPE) to 
generate an optical density ratio with arbitrary units that showed good correlation 
with vitreous haze score, but further validation was required. First, the original 
study was too small to allow subgroup analysis of common patient factors that 
might render the technique unreliable, notably phakic status or previous 
vitreoretinal surgery. Second, the original study employed an OCT device from a 
single vendor (Spectralis OCT, Heidelberg Engineering, Germany), raising the 
possibility that the method might not be applicable across other medical systems. 
Third, these preliminary findings needed to be confirmed in a different patient 
cohort, using a different team of OCT technicians and independent analysers to 
ascertain whether the method has applicability to and may be adopted by multiple 
end-users.   
 
To these ends this study aims to evaluate the previously proposed OCT-derived 
vitritis quantification method in a larger series of intermediate, posterior and 
panuveitis eyes, using an alternative spectral domain OCT platform in a 
geographically and demographically distinct study population. Such data would 
deliver an independent evaluation of an ability to obtain objective, continuous and 
reproducible measurements of vitreous inflammation. A further aim is to determine 
the influence of phakic status or previous vitreo-retinal surgery on these objective 
measurements. 
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Methods 
All OCT image sets were obtained from patients attending a tertiary referral uveitis 
clinic (AA) at Institut Clínic d´Oftalmología (ICOF), Hospital Clinic, Barcelona, 
Spain. Patients included in the study had intermediate, posterior or panuveitis of 
different etiologies, with varying degrees of vitreous inflammation, and 
corresponding OCT image sets captured during routine clinical care, from a 6 year-
period (November 2009-June 2014). This study was approved by the Ethics 
Committee of the Hospital Clinic, Barcelona and was conducted in accordance with 
the Declaration of Helsinki. 
 
Clinical Data 
Demographic data collected from patients in the study included age, gender, 
uveitis anatomical location, uveitis etiology, current treatment, and any history of 
previous intraocular surgery. Clinical characteristics of study eyes collected 
include: 1) best measured visual acuity (BMVA); 2) presence of keratic 
precipitates; 3) presence of posterior synechiae; 4) phakic status, classified as: a) 
phakic; b) pseudophakic; and c) aphakic; 5) anterior chamber (AC) activity and 6) 
vitreous haze score using standardized protocols according to the NEI and SUN 
guidelines.1, 2 All clinical data were collected during routine clinical care in an 
electronic medical records system and extracted for analysis. Only eyes with 
complete information of the above fields and corresponding OCT images were 
included in the analysis (Supplemental figure 1, available online at 
www.aaojournal.org). 
 
Optical Coherence Tomography Image Acquisition Protocol 
All SD-OCT image sets included in this study were acquired using a spectral-
domain OCT system (Cirrus HD-OCT, Carl Zeiss Meditec, Dublin, California) with 
the standard ‘Macular Cube’ protocol. The Macular Cube protocol consists of 128 
horizontally oriented B-scans acquired in a continuous, automated sequence and 
covers a 6 mm × 6 mm area. Each B scan is 6 mm in length and composed of 512 
equally spaced transverse sampled locations. The enhanced depth imaging mode 
was not used in any case, and the point of maximum sensitivity or zero delay line 
was maintained in the vitreous side.6 For the purposes of this study, only scans 
centered in the fovea were analyzed. 
 
Qualitative Analysis of Optical Coherence Tomography images 
SD-OCT images were qualitatively analyzed to assess the presence of 1) 
hyperreflective dots, larger and with greater density than background speckle noise 
as surrogate marker of cellular infiltrates into the vitreous;7 2) presence of epiretinal 
membrane preventing adequate transmission of light to the retinal pigment 
epithelium; and 3) severe anatomical disruption of retinal integrity and outer retinal 
layers/RPE status, preventing adequate delineation of the retinal pigment 
epithelium compartment of interest for the quantitative analysis. All cases with 2) 
and 3) were excluded from the subsequent quantitative analysis. Examples of 
clinical cases excluded are described in Supplemental Figure 2 (available online at 
www.aaojournal.org). 
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Quantitative Analysis of Optical Coherence Tomography images 
Raw SD-OCT images were exported from the Cirrus HD-OCT system and 
imported into OCTOR (Doheny Eye Institute, Los Angeles, California), custom 
grading software that allows manual delineation of boundaries that define the 
compartments of interest.8-10 In each case, boundaries were manually segmented 
as per a previously described protocol for 3 B-scans passing through the foveal 
central subfield (central subfield of the Early Treatment Diabetic Retinopathy Study 
chart) by an experienced grader (JZV) masked to clinical vitreous haze score 
values.5 The boundaries were: a) Vitreous top, the uppermost extent of vitreous 
space included in the OCT image; b) internal limiting membrane (ILM), the inner 
boundary of the neurosensory retina; c) RPE-inner limit, the inner boundary of the 
RPE; and d) RPE-outer limit, the outer boundary of the RPE. These boundaries 
delineate the following spaces: 1) vitreous, defined as the space between the 
vitreous top and ILM (except cases with incomplete posterior vitreous detachment, 
where the innermost limit of the vitreous hyaloid was chosen, as including this 
retrohyaloid space filled with optically hyporeflective aqueous may infraestimate 
the absolute intensity of the compartment); and 2) RPE, defined as the space 
between the RPE-inner and the RPE-outer boundaries (Figure 1). The intensity of 
all pixels included in each of these compartments was summed to generate a 
corresponding mean OCT intensity value for the total scanned area, described as 
“VIT-absolute intensity” and “RPE-absolute intensity”, respectively. Finally, an 
arbitrary ratio was generated with these two values and expressed as “VIT/RPE 
relative intensity” (“VIT-absolute intensity”/“RPE-absolute intensity”). 
 
Statistical methods 
Descriptive and frequency statistics were used to assess qualitative variables. 
Normality of quantitative variables (i.e. VIT/RPE intensity ratios) was examined 
using histograms. To assess differences in VIT/RPE mean intensity between study 
groups, non-parametric Mann-Whitney U-test and Kruskal-Wallis test were 
employed for 2-to-2 and ≥3 groups comparisons, respectively. Correlation between 
VIT/RPE intensity ratios and vitreous haze score was analyzed using non-
parametric Spearman test, and a multivariable regression model was applied to 
assess the effects of clinical characteristics on SD-OCT intensity values. Visual 
acuity measured in Snellen notation was converted to logMAR (logarithm of the 
minimum angle of resolution) equivalents for the purposes of statistical analysis. 
VA values recorded as counting fingers (CF), hand movements (HM), and 
perception of light (PL) were converted to 2.1, 2.4, and 2.7 LogMAR, respectively.11 
A p value of less than 0.05 was considered statistically significant. All statistical 
analysis was performed using SPSS 15.0 software (SPSS Inc., Chicago, Illinois). 
 
Results 
Baseline Characteristics 
 Among the cohort of patients seen in the uveitis unit in the study period, 105 eyes 
with intermediate, posterior or pan-uveitis had complete clinical data with 
corresponding OCT images and were included in the study (Supplemental figure 1, 
available online at www.aaojournal.org). Demographics and baseline 
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characteristics of study eyes are summarized in Table 1, disclosed by total eyes 
and eyes with and without vitritis (vitritis defined as vitreous haze score ≥+0.5) for 
comparison purposes. 
 
Optical Coherence Tomography-derived Measurements of Vitreous Intensity 
The OCT-derived VIT/RPE relative intensity measurements for each vitreous haze 
score grade are represented in Figures 2 and 3 and Table 2. Significant differences 
were observed between eyes without vitritis (Vitreous haze score = 0, median 
0.3456, interquartile range 0.024) and eyes with vitritis (Vitreous haze score ≥ +0.5, 
median 0.3670, interquartile range 0.040)(p < 0.001). Differences in VIT/RPE 
relative intensity values were also significant between study eyes disclosed by 
vitreous haze score clinical grade (p < 0.001) (Figure 3). A significant correlation 
was observed between VIT/RPE relative intensity measurements and vitreous 
haze score clinical grade (r = 0.535, p < 0.001), AC cells (r = 0.246, p = 0.01) and 
AC flare (r = 0.215, p = 0.02). No significant differences were observed for VA (r = 
0.182, p = 0.06), however, once eyes with very poor VA were excluded from 
analysis (3 eyes excluded, “counting fingers”, n = 2, and “hand movements”, n = 1) 
this correlation was also significant (r = 0.198, p = 0.04). Figure 4 represents the 
correlation between VIT/RPE relative intensity values and vitreous haze score 
clinical grades. After adjusting for factors governing media clarity (such as AC 
cells, AC flare and phakic status) in a stepwise multivariable model, VIT/RPE 
relative intensity values remained independently associated with vitreous haze 
score clinical grades (R2-adjusted = 0.424, p < 0.001).  
 
Influence of Phakic Status 
Among the 105 eyes included in the study, 69 were phakic (65.7%), 32 were 
pseudophakic (30.5%) and four were aphakic (3.8%). No significant differences 
were observed in VIT/RPE relative intensity values between phakic (median = 
0.3522, interquartile range = 0.028) and pseudophakic eyes (median = 0.3577, 
interquartile range = 0.027) (p = 0.48). When eyes were categorised by vitreous 
haze score clinical grades, no significant differences were observed in the VIT/RPE 
relative intensity values between phakic and pseudophakic eyes (Figure 5) with a 
vitreous haze score of 0 (median = 0.3461, interquartile range = 0.021, median = 
0.3483, interquartile range = 0.025, p = 0.91), + 0.5 (median = 0.3595, interquartile 
range 0.027, median = 0.3646, interquartile range = 0.031, p = 0.91), or + 1 
(median = 0.3642, interquartile range = 0.037, median = 0.3658, interquartile range 
= 0.029, p = 0.87), respectively (Table 3). For purposes of clarity, aphakic eyes (n 
= 4) and eyes with vitreous haze score ≥ 2 (n = 12) have not been included in 
Figure 5.  
 
Influence of Previous Pars plana Vitrectomy 
At the time of OCT scanning, 92 eyes were non-vitrectomized (87.6%) and 13 eyes 
had undergone previous pars plana vitrectomy (12.4%). VIT/RPE relative intensity 
values were not significantly different between non-vitrectomized eyes (median = 
0.3540, interquartile range = 0.032) and vitrectomized eyes (median = 0.3580, 
interquartile range = 0.021) (p = 0.52). In the subgroup analysis by vitreous haze 
score clinical grades, no significant differences were observed between non-
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vitrectomized and vitrectomized eyes for vitreous haze score of 0 (median = 
0.3459, interquartile range = 0.024, median = 0.3461, interquartile range = 0.014, p 
= 0.21), + 0.5 (median = 0.3595, interquartile range 0.028, median = 0.3670, 
interquartile range = 0.001, p = 0.61), or + 1 (median = 0.3667, interquartile range 
= 0.034, median = 0.3568, interquartile range = 0.001, p = 0.91), respectively 
(Figure 6). For purposes of clarity, eyes with vitreous haze score ≥ +2 (n = 12) 
have not been included in Figure 6. 
 
Discussion: 
Data from this current feasibility, early validation cohort supports the findings of the 
previous proof-of-concept study.5 The data extends previous findings and delivers 
a rationale for and adoption of objective, continuous and reproducible OCT-derived 
measurements of vitreous inflammation in the clinical and trials setting. We show 
that the technique is reproducible with a different spectral domain OCT device and 
in a different cohort of uveitis patients. Importantly, the data also gives evidence 
that the method may be valid regardless of phakic status or previous pars plana 
vitrectomy. 
 
In recent years the rapid advancement of OCT acquisition speed and its 
ability to image through ocular media has enabled visualisation of some aspects of 
inflammation within the eye, opening the door to correlate OCT-derived images 
with clinical assessments.5, 10, 12 The method employed in this study is based in the 
determination of absolute measurements of vitreous and RPE signal intensities, 
reflecting the mean intensity value for all image pixels contained within these 
compartments. Then, to reduce the effects of OCT signal strength and media 
opacities, both values are combined to obtain a ratio with arbitrary units, which can 
then be compared to clinical vitreous haze score. The use of optical density ratios 
has also previously been evaluated in subretinal and intraretinal fluid as a 
biomarker of different retinal diseases, such as age-macular degeneration, central 
serous chorioretinopathy, or diabetic retinopathy.13, 14  
 
The findings reported in this study further corroborate the method proposed 
by Keane et al5, testing the resilience of this technique against a number of 
technical and clinical challenges. A key finding is that we have shown that this is 
not device specific. There is a difference in the relative intensity values for the 
same level of vitreous haze score between the studies (i.e. for vitreous haze score 
= +1, this study = 0.3663, and for Keane et al = 0.2222). Assuming that this is not 
due to variability in grading between different sets of clinicians across the two 
studies, then the data would imply that the absolute measurements are device-
specific, and may be related to technical differences in the laser source and/or 
optical lens system of each OCT platform. Nevertheless significance of correlation 
to clinical scores is maintained. Differences between OCT devices have been 
demonstrated for a variety of OCT-derived measurements such as retinal and 
choroidal thickness or volume. 15-17 Whether this apparent difference is a device 
effect or arises due to variability of clinical practice needs further clarification 
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through performing sequential scans on the same patient on the same day across 
devices, and this work is ongoing.  
 
If there is shown to be a real difference in absolute values between devices 
then our recommendations would be that (1) longitudinal assessments in clinical 
studies should all be made using the same OCT machine (as is indeed current 
practice); (2) all OCT machines that are to be used in this way need head-to-head 
studies vs a gold-standard to enable comparison between platforms, and the 
development of correction factors. In the future such correction factors can be 
incorporated into each OCT platform so that the clinician is provided with a 
corrected OCT-measured Vitreous/RPE relative intensity score (cVIT/RPE) that is 
directly comparable across platforms. It is worth noting that the value of the 
technique is best highlighted by its potential role in measuring response to 
treatment, similar to the use of central macular thickness (CMT) in assessing 
improvement in cystoid macular edema (CME). In both scenarios it is the direction 
of change, the relative magnitude and the return to normality that are the criteria by 
which treatment success is measured, and as such the absolute values are less 
important.  
 
Another important finding of the study was the demonstration that the 
technique does not appear to be affected by phakic status or previous vitrectomy. 
Both pseudophakia and previous vitrectomy surgery are common scenarios in the 
uveitic population (30% and 12% respectively in this study cohort) and thus 
alterations in the VIT/RPE relative intensity arising from these surgical 
interventions would have been a significant challenge to the utility of the technique 
in daily practice. The use of a ratio relating the absolute values of optical reflectivity 
in the vitreous to the RPE layer was chosen so as to compensate for potential 
differences in laser beam transmission through the media of the anterior segment 
(including phakic status), and this is further justified by the results of this study.  
We recognise that this was a retrospective cohort study, with the inherent 
challenges that brings. Of relevance is that the vitreous haze score was assessed 
as part of routine care by a single clinician, rather than by two independent 
clinicians as was done in the Keane et al. paper.5 It should be noted however that 
this is common practice in clinical trials, even those in which vitreous haze score is 
the primary endpoint. One advantage of the retrospective design is that it 
demonstrates the utility of this technique in unselected scans taken as part of 
routine practice with no additional special measures, and that if this technique 
became widely used it could also be applied to historical scans providing a huge 
resource both for further research and to inform decision making in the clinic. 
Although not supported by the current data, a potential bias remains when 
analysing and comparing non-vitrectomized versus vitrectomized eyes with respect 
to a potential over-estimate of optical density in non-vitrectomized eyes. The major 
limitation highlighted by this study was the burden of performing this technique 
manually. On average each scan took 5-10 mins when conducted by an 
experienced grader. This would be prohibitive for routine clinical use. In light of this 
we have recently developed custom VITreous ANalysis software (termed ‘VITAN’), 
which is fully automated and avoids the need for manual segmentation.18 This has 
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been validated on the original cohort described in the Keane et al paper, and was 
shown to perform accurate segmentation in 100% scans. Results were comparable 
to those with the manual technique, with a slightly higher correlation with clinical 
vitreous haze scores than that reported using manual segmentation in our previous 
study. Critically VITAN analyses each scan in < 2 seconds, enabling immediate 
assessment at the point-of-contact, ideal for routine clinical use.  
   
In summary, we have demonstrated that SD-OCT measurement of VIT/RPE 
relative intensity using the Cirrus instrument is a robust measure of vitreous haze 
which correlates with the clinical vitreous haze score, and which is not limited by 
phakic state or previous vitrectomy. Such measures hold immense promise but 
require further validation, a key part of which will be in their use as exploratory 
endpoints in prospective multicentre interventional studies. This study forms part of 
the Extended OCT-Quantification of Uveitis Activity for Trial Outcomes and 
Reporting (EQUATOR) programme, the purpose of which is to develop and 
validate objective imaging-based measures of ocular inflammation for use in 
clinical trials and routine clinical practise and which would in time replace the 
current subjective clinical measures we depend on. In this area, it is encouraging to 
see progress being made by groups around the world regarding the assessment of 
other such variables notably AC cells12, 19, 20 and retinovascular leakage.21 The 
development and validation of such techniques supported by increasingly sensitive 
OCT instruments capable of imaging larger volumes of the eye will revolutionise 
both clinical practice and the ability of clinical trials to demonstrate treatment 
efficacy.
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Figure Captions: 
 
Figure 1. Segmentation protocol for quantitative analysis of the vitreous with 
OCTOR (Doheny Image Reading Center, Los Angeles, CA). Spectral domain 
optical coherence tomography (SD-OCT) (Cirrus HD-OCT, Carl Zeiss Meditec, 
Dublin, CA) B-scan obtained from a 54-year-old patient with Vogt-Koyanagi-Harada 
disease-related panuveitis and moderate vitreous haze (clinical vitreous haze score 
+2). [Top]: Raw SD-OCT B-scan. [Middle]: Boundaries segmented manually with 
OCTOR (top white line, arrowhead=vitreous top; pink line, asterisk=internal limiting 
membrane (ILM); superior white arrow, white line=retinal pigment epithelium 
(RPE)-inner boundary; inferior white arrow, white line=RPE-outer boundary). 
[Bottom]: Segmentation of the vitreous and the RPE compartments defined by the 
above boundaries (vitreous=grey, retina=pink, RPE=brown). Vitreous signal 
intensity/RPE (VIT/RPE)-relative intensity of 0.4146.  
 
Figure 2. Visualization of inflammatory changes in the vitreous using spectral-
domain optical coherence tomography (SD-OCT) (Cirrus HD-OCT, Carl Zeiss 
Meditec, Dublin, CA). [Top], SD-OCT B-scan obtained from a 32 year-old patient 
with quiescent intermediate uveitis related to systemic lupus erythematosus and no 
signs of vitritis (clinical vitreous haze score 0, vitreous signal intensity/retinal 
pigment epithelium (VIT/RPE)-relative intensity 0.3292). [Middle-Top], SD-OCT B-
scan of a 45-year-old patient with sarcoid-related panuveitis demonstrating minimal 
vitreous haze (clinical vitreous haze score +0.5, VIT/RPE-relative intensity 0.3522). 
[Middle], SD-OCT B-scan obtained from a 39 year-old patient with sympathetic 
ophthalmia demonstrating moderate vitreous haze (clinical vitreous haze score +1, 
VIT/RPE-relative intensity 0.3652). [Middle-Bottom], SD-OCT B-scan obtained 
from a 26 year-old patient with posterior uveitis related to Behçet's disease 
demonstrating moderate to severe vitreous haze (clinical vitreous haze score +2, 
VIT/RPE-relative intensity 0.4328). [Bottom], SD-OCT B-scan obtained from a 44-
year-old patient with intermediate uveitis related to multiple sclerosis demonstrating 
severe vitreous haze (clinical vitreous haze score +3, VIT/RPE-relative intensity 
0.5652). 
 
Figure 3. Box-plots showing vitreous signal intensity/retinal pigment epithelium 
(VIT/RPE)-Relative intensity measurements for each clinical grade of vitreous 
haze. The horizontal lines within each box represent the median for each group, 
the ends of the boxes are the upper and lower quartiles and the whiskers represent 
minimum and maximum values.  
 
Figure 4. Scatter plot comparing clinical vitreous haze scores with vitreous signal 
intensity/retinal pigment epithelium (VIT/RPE)-relative intensity values. The solid 
line represents the regression line.  
 
Figure 5. Subgroup analysis of vitreous signal intensity/retinal pigment epithelium 
(VIT/RPE)-relative intensity measurements by phakic status. Box-plots showing 
VIT/RPE-relative intensity measurements for each clinical grade of vitreous haze in 
phakic (dark grey) and pseudophakic (light grey) eyes. The horizontal lines within 
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each box represent the median for each group, the ends of the boxes are the 
upper and lower quartiles and the whiskers represent minimum and maximum 
values. 
 
Figure 6. Subgroup analysis of vitreous signal intensity/retinal pigment epithelium 
(VIT/RPE)-relative intensity measurements by previous vitreo-retinal surgery. Box-
plots showing VIT/RPE-relative intensity measurements for each clinical grade of 
vitreous haze in non-vitrectomized (dark grey) and vitrectomized (light grey) eyes. 
The horizontal lines within each box represent the median for each group, the ends 
of the boxes are the upper and lower quartiles and the whiskers represent 
minimum and maximum values. 
 
Supplemental Figure 1. Consolidated standards of reporting trials-style diagram 
showing the number of excluded and included eyes in the study which underwent 
assessment with the optical coherence tomography vitritis grading method 
(supplemental material available at AJO.com). 
 
Supplemental Figure 2. Examples of cases in which the proposed vitritis grading 
method with optical coherence tomography cannot be applied. [Top], B-scan 
obtained from a 50–year-old patient with sympathetic ophthalmia and extensive 
retinal pigment epithelium (RPE) atrophy. [Middle-Top], B-scan from an 85 year-
old patient with sarcoid-related panuveitis with thick epiretinal membrane 
preventing adequate penetrance of light up to the RPE. [Middle-Bottom], B-scan 
obtained from a 71 year-old patient with non-differentiated panuveitis showing 
severe anatomical distortion preventing adequate identification of RPE inner and 
outer boundaries. [Bottom], B-scan obtained from a 42 year-old patient with Vogt-
Koyanagi-Harada disease demonstrating serous retinal detachments, with severe 
architectural damage at the outer retinal layers preventing adequate delineation of 
the RPE boundaries (supplemental material available at AJO.com).  
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PhD FRCOphth5,6,7 , Andrew D. Dick MD, FMedSci,8,9 Michael Karampelas MD, 
FEBO,8,10 Pearse A. Keane MD, FRCOphth,8 Richard W. Lee MRCOphth, PhD,8,9 
Philip I. Murray PhD, FRCOphth,6,7 Robert B. Nussenblatt MD, MPH,11 Carlos E. 
Pavesio MD, FRCOphth,8 Srinivas R. Sadda MD,12 H. Nida Sen MD, MHSc,11 
Dawn A. Sim FRCOphth,8 Adnan Tufail MD, FRCOphth,8 Javier Zarranz-Ventura 
MD, PhD, FEBO1,8,9 
 
1Institut Clínic d´Oftalmologia, Hospital Clinic, Barcelona, Spain 
2Manchester Royal Eye Hospital, Central Manchester University Hospitals National Health Service 
Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom 
3Faculty of Medical and Human Sciences, University of Manchester, United Kingdom  
4School of Built Environment, Herriot-Watt University, United Kingdom 
5Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham National Health Service 
Foundation Trust, Birmingham, United Kingdom 
6Academic Unit of Ophthalmology, University of Birmingham, Birmingham, United Kingdom 
7Birmingham & Midland Eye Centre, Sandwell and West Birmingham National Health Service Trust, 
Birmingham, United Kingdom 
8National Institute of Health Research Biomedical Research Centre for Ophthalmology, Moorfields 
Eye Hospital National Health Service Foundation Trust and University College London Institute of 
Ophthalmology, United Kingdom 
9Academic Unit of Ophthalmology, University of Bristol, Bristol, United Kingdom 
10Hinchingbrooke Hospital, Hinchingbrooke Health Care National Health Service Trust, United 
Kingdom 
11National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States 
12Doheny Eye Institute, University of California Los Angeles, California, United States 
 
 
Table 1. Demographics and baseline clinical characteristics of study eyes analysed 
with the optical coherence tomography vitritis grading method and subgroup 
analysis by no vitritis and vitritis eyes. 
 
 Total Uveitis 
eyes 
Uveitis eyes 
No Vitritis 
Uveitis eyes 
Vitritis 
Age, mean ± SD 45.3 ± 16.4 46.6 ± 14.8 44.0 ± 17.9 
VA, mean ± SD 
(logMAR) 
0.30 ± 0.38 0.28 ± 0.4 0.33 ± 0.35 
Phenotypic 
diagnosis, no. (%) 
   
- Behçet's 24 (22.8) 14 (25.9) 10 (19.6) 
- Birdshot 22 (20.9) 10 (18.5) 12 (23.5) 
- Sarcoid 14 (13.3) 9 (16.6) 5 (9.8) 
- Non-differentiated 11 (10.4) 3 (5.5) 8 (15.6) 
- Pars planitis 8 (7.6) 5 (9.2) 3 (5.8) 
- VKH 6 (5.7) 2 (3.7) 4 (7.8) 
- Multiple sclerosis 4 (3.8) 1 (1.8) 3 (5.8) 
- Other 16 (15.2) 10 (18.5) 6 (11.7) 
Uveitis anatomic 
classification, no. 
(%) 
   
- Intermediate 34 (32.3) 14 (25.9) 20 (39.2) 
- Posterior 36 (34.2) 19 (35.1) 17 (33.3) 
- Panuveitis 35 (33.3) 21 (38.8) 14 (27.4) 
Keratic precipitates, 
no. (%) 
11 (10.4) 4 (7.4) 7 (13.7) 
Posterior synechiae, 
no. (%) 
7 (6.6) 5 (9.2) 2 (3.9) 
Phakic status, no. 
(%) 
   
a. Phakic 71 (67.5) 35 (64.7) 36 (70.5) 
- Clear lens 47 (44.7) 22 (40.7) 25 (49.0) 
- Cataract 24 (22.8) 13 (24.0) 11 (21.5) 
b. Pseudophakic 30 (28.5) 16 (29.6) 14 (27.4) 
c. Aphakic 4 (3.8) 3 (5.5) 1 (1.9) 
d. Posterior capsular 
opacification, no. 
(%) 
6 (5.7) 3 (5.5) 3 (5.8) 
AC cells, no. (%)    
0 85 (80.9) 52 (96.2) 33 (64.7) 
0.5+ 8 (7.6) 2 (3.7) 6 (11.7) 
1+ 8 (7.6) 0 (0) 8 (15.6) 
2+ 3 (2.8) 0 (0) 3 (5.8) 
Table 1
3+ 0 (0) 0 (0) 0 (0) 
4+ 1 (0.9) 0 (0) 1 (1.9) 
AC flare, no. (%)    
0 96 (91.4) 54 (100) 42 (82.3) 
1+ 6 (5.7) 0 (0) 6 (11.7) 
2+ 2 (1.9) 0 (0) 2 (3.9) 
3+ 1 (0.9) 0 (0) 1 (1.9) 
4+ 0 (0) 0 (0) 0 (0) 
Vitreous Haze 
Score, no. (%) 
   
0 54 (51.4) 54 (100) 0 (0) 
0.5+ 21 (20) 0 (0) 21 (41.1) 
1+ 18 (17.1) 0 (0) 18 (35.2) 
2+ 9 (8.5) 0 (0) 9 (17.6) 
3+ 3 (2.8) 0 (0) 3 (5.8) 
4+ 0 (0) 0 (0) 0 (0) 
 
(AC = Anterior chamber; logMAR = logarithm of the minimum angle of resolution; 
SD = standard deviation; VA = visual acuity; VKH = Vogt-Koyanagi-Harada 
disease). 
 
Table 2. Comparison of vitreous / retinal pigment epithelium (VIT/RPE) relative 
intensity values between vitreous haze score subgroups, considering vitreous haze 
score = 0 as reference group. 
 
 
 
(* p<0.05 = significant; IQR = interquartile range; n/a = not applicable).   
 
Vitreous Haze 
Score 
VIT/RPE Relative 
intensity 
(median) 
P value 
0 0.3456 
IQR 0.022 
(n=54) 
(reference) 
0.5+ 0.3623 
IQR 0.027 
(n=21) 
0.009* 
1+ 0.3663 
IQR 0.036 
(n=18) 
<0.001* 
2+ 0.3884 
IQR 0.063 
(n=9) 
0.002* 
3+ 0.3915 
IQR n/a 
(n=3) 
<0.001* 
4+ n/a 
(n=0) 
n/a 
Total (n) 105  
Table 2
 1 
 
Table 3. Comparison of vitreous / retinal pigment epithelium (VIT/RPE) relative 
intensity values between study eyes disclosed by phakic status and previous pars 
plana vitrectomy at different levels of vitreous haze score. 
 
 Phakic status Previous Pars Plana 
Vitrectomy 
Vitreous 
Haze 
Score 
Phakic Pseudophakic P 
value 
No PPV PPV P value 
0 0.3461 
IQR 
0.3461 
(n=35) 
0.3483 
IQR 0.025 
(n=16) 
0.91 0.3459 
IQR 
0.024 
(n=46) 
0.3461 
IQR 
0.014 
(n=8) 
0.21 
0.5+ 0.3595 
IQR 
0.027 
(n=13) 
0.3646 
IQR 0.031 
(n=8) 
0.91 0.3595 
IQR 
0.028 
(n=19) 
0.3670 
IQR n/a 
(n=2) 
0.61 
1+ 0.3642 
IQR 
0.037 
(n=12) 
0.3658 
IQR 0.029 
(n=5) 
0.87 0.3667 
IQR 
0.034 
(n=15) 
0.3568 
IQR n/a 
(n=3) 
0.91 
2+ 0.3959 
IQR 
0.075 
(n=8) 
0.3756 
IQR n/a 
(n=1) 
0.66 0.3900 
IQR 
0.052 
(n=9) 
n/a 
(n=0) 
n/a 
3+ 0.3776 
IQR n/a 
(n=1) 
0.4784 
IQR n/a 
(n=2) 
0.66 0.3915 
IQR n/a 
(n=3) 
n/a 
(n=0) 
n/a 
4+ n/a 
(n=0) 
n/a 
(n=0) 
n/a n/a 
(n=0) 
n/a 
(n=0) 
n/a 
Total (n) 69 32  92 13  
 
(* p<0.05 = significant; IQR = interquartile range; PPV = pars plana vitrectomy; n/a 
= not applicable). 
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